ROMK potassium channel blocker

oral eff. in hypertension model (1 mpk QD)

backup candidate to MK-7145 (Ph. Ib)

J. Med. Chem., May 26, 2021

Merck & Co., Kenilworth, NJ

The Merck ROMK potassium channel blocker, MK-8153, is a backup development candidate to MK-7145, whose development as a diuretic was terminated after a Ph. Ib study due to lack of…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.